Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17980034 | 0.81 | SLC6A4 (0.33) | SLC6A4SLC6A3KDM1ACYP2D6TACR1 | |
| SCHEMBL17980202 | 0.81 | SLC6A4 (0.33) | SLC6A4SLC6A3KDM1ACYP2D6TACR1 | |
| SCHEMBL17980296 | 0.81 | SLC6A4 (0.33) | SLC6A4SLC6A3KDM1ACYP2D6TACR1 | |
| SCHEMBL17980015 | 0.81 | SLC6A4 (0.33) | SLC6A4SLC6A3KDM1ACYP2D6TACR1 | |
| SCHEMBL17980027 | 0.81 | SLC6A4 (0.33) | SLC6A4SLC6A3KDM1ACYP2D6TACR1 | |
| SCHEMBL17980071 | 0.81 | SLC6A4 (0.33) | SLC6A4SLC6A3KDM1ACYP2D6TACR1 | |
| SCHEMBL18032809 | 0.72 | SRD5A1 (0.45) | SLC6A4SLC6A3KDM1A | |
| SCHEMBL25436834 | 0.71 | SLC6A4 (0.34) | SLC6A4SLC6A3KDM1ACYP2D6 | |
| SCHEMBL25438960 | 0.71 | SLC6A4 (0.34) | SLC6A4SLC6A3KDM1ACYP2D6 | |
| SCHEMBL25436830 | 0.71 | SLC6A4 (0.34) | SLC6A4SLC6A3KDM1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185799-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185799-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | CNR1, HCRTR1, CNR2 | SLC6A4 410/4885SLC6A3 200/4885KDM1A 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.